Soleno Therapeutics SLNO 深 沪
等待开盘 02-06 09:30:00 美东时间
39.58
-2.540
-6.03%
华盛通- 最 高42.71
- 今 开42.14
- 成交量 123.15万股
- 最 低 39.23
- 昨 收 42.12
- 总市值 20.88亿
- 52周最高 90.3199
- 市盈率 静 --
- 换手率 2.33%
- 52周最低 37.95
- 委 比 97.14%
- 总股本 5274.69万
- 历史最高 90.3199
- 量 比 0.53
- 振 幅 8.26%
- 历史最低 1.81
- 每 手 1
- 风险率 14.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining more than 350 points ...
02-02 23:44
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics将参加2026年2月和3月的三项投资者会议：Guggenheim Biotech Summit（2月12日，Fireside Chat）、Oppenheimer Healthcare Conference（2月26日，公司演示）和TD Cowen Health Care Conference（3月4日，Fireside Chat）。Soleno致力于开发治疗罕见病的新型疗法，其产品VYKAT™ XR已获FDA批准用于治疗Prader-Willi综合征患者的过度进食症状。会议直播及回放可通过公司网站获取。
01-29 13:00
Soleno Therapeutics Updates Executive Compensation and Severance Plans
Soleno Therapeutics ( ($SLNO) ) just unveiled an announcement. On January 21, 2...
01-24 06:45
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
HC Wainwright & Co. Maintains Buy on Soleno Therapeutics, Raises Price Target to $120
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the price target from $110 to $120.
01-20 19:48
Soleno Therapeutics Announces Peer-Reviewed JCEM Publication Highlighting VYKAT XR Withdrawal Period Study In Prader-Willi Syndrome
Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical
01-05 21:17
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
Soleno Therapeutics announced the publication of a study in the *Journal of Clinical Endocrinology and Metabolism* detailing a 16-week randomized withdrawal study of VYKAT™ XR (diazoxide choline extended-release tablets) for treating hyperphagia in Prader-Willi syndrome (PWS). The study, part of a Phase 3 clinical program, demonstrated that discontinuing VYKAT XR led to significant worsening of hyperphagia compared to continued treatment. VYKAT X...
01-05 13:00
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.
2025-12-12 02:17
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Soleno Therapeutics announce the passing of Bill Harris, a valued Board member and Audit Committee Chairman since 2014. Harris, known for his integrity and expertise, had a prominent career in biopharmaceutical finance. Andrew Sinclair, a long-serving Board member, will assume the Audit Committee Chair position. Soleno focuses on rare disease therapeutics, with its FDA-approved VYKAT™ XR for Prader-Willi syndrome hyperphagia.
2025-12-03 21:05
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
